Other languages Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
1.76 ^USD	-11.56%		+29.41%	+38.58%

16/05	Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
09/05	Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	09/05
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03/04
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	07/03
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	07/02
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29/01
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	19/12
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro	04/12
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment	16/23/16
Sector Update: Health Care Stocks Advancing Late Afternoon	05/23/05
Sector Update: Health Care Stocks Lower Wednesday Afternoon	04/23/04
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Potential Multiple System Atrophy Treatment	04/23/04
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib	24/23/24
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro	17/23/17
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Top Premarket Gainers	30/23/30
Inhibikase Therapeutics to Implement 1-for-6 Reverse Stock Split	29/23/29
Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study	22/23/22
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Other languages

Filters